{"success":true,"data":{"pressRelease":{"id":"164199","rtpr_id":"nBw59vX58a-20261008","ticker":"LTRN","exchange":"NASDAQ","all_tickers":["LTRN"],"title":"Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 15th, 2026","author":"Business Wire","published_at":"2026-10-08T12:00:01.527Z","article_body":"Lantern Pharma to Present at the ThinkEquity Conference in NYC on October\n15th, 2026\n\nLantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”)\ncompany developing targeted and transformative cancer therapies using its\nproprietary RADR(®) AI and machine learning (“ML”) platform with multiple\nclinical stage drug programs, today announced that Lantern management will be\npresenting at the ThinkEquity Conference on Thursday, October 15, 2026, at\n3:30 p.m. ET at the Mandarin Oriental in New York, NY.\n\n * Webcast Link: \nhttps://event.summitcast.com/view/GXv6JAoMEphytK6ggozCk7/VS4pGMrvkgq2xwHrNQevWX\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fevent.summitcast.com%2Fview%2FGXv6JAoMEphytK6ggozCk7%2FVS4pGMrvkgq2xwHrNQevWX&esheet=54618155&newsitemid=20261008156050&lan=en-US&anchor=https%3A%2F%2Fevent.summitcast.com%2Fview%2FGXv6JAoMEphytK6ggozCk7%2FVS4pGMrvkgq2xwHrNQevWX&index=1&md5=2e0fec7a96fb37b1002bd390822a267d)\n * Conference Registration Link: \nhttps://www.meetmax.com/sched/event_138793/conference_register.html\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.meetmax.com%2Fsched%2Fevent_138793%2Fconference_register.html&esheet=54618155&newsitemid=20261008156050&lan=en-US&anchor=https%3A%2F%2Fwww.meetmax.com%2Fsched%2Fevent_138793%2Fconference_register.html&index=2&md5=7e27767e4ff2a66e32b0c0c28fc19ad7)\nLantern Pharma management will be available for one-on-one meetings held\nthroughout the conference.\n\nAbout Lantern Pharma\n\nLantern Pharma Inc. (NASDAQ: LTRN) is a clinical-stage, AI-driven precision\noncology company developing targeted therapies for high-need cancer\nindications. The Company’s proprietary RADR® AI platform integrates\nmulti-omic biomarker data with clinical outcomes to identify patient subgroups\nmost likely to respond to specific therapies, enabling more efficient clinical\ndevelopment and biomarker-driven trial design. Lantern’s pipeline includes\nLP-300 (HARMONIC™ trial in never-smoker NSCLC), LP-184, and LP-284, with\nadditional preclinical programs identified through RADR®.\n\nFor more information, visit:\n\n * Website: \nwww.lanternpharma.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.lanternpharma.com&esheet=54618155&newsitemid=20261008156050&lan=en-US&anchor=www.lanternpharma.com&index=3&md5=8562d72ec455aa97ec03e0da5129bddc)\n * LinkedIn: \nhttps://www.linkedin.com/company/lanternpharma/\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Flanternpharma%2F&esheet=54618155&newsitemid=20261008156050&lan=en-US&anchor=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Flanternpharma%2F&index=4&md5=0d917bbd2e28f0fe0bf464b8381d22fd)\n * X: @lanternpharma\nForward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nSection 27A of the Securities Act of 1933, as amended, and Section 21E of the\nSecurities Exchange Act of 1934, as amended. These forward-looking statements\ninclude, among other things, statements relating to: future events or our\nfuture financial performance; the potential advantages of our RADR(®) and\nOpen-Medicine AI platforms in identifying drug candidates, accelerating drug\ndevelopment, and generating revenue through software licensing and\nsubscription models; our strategic plans to advance the development of our\ndrug candidates; the planned commercialization of our AI platforms, including\nOpen-Medicine AI; estimates regarding the development timing for our drug\ncandidates and AI platforms; our research and development efforts of our\ninternal drug discovery programs and the utilization of our AI platforms to\nstreamline the drug development process; estimates regarding patient\npopulations, potential markets and potential market sizes; and our plans to\ndiscover and develop drug candidates and to maximize their commercial\npotential by advancing such drug candidates ourselves or in collaboration with\nothers.\n\nAny statements that are not statements of historical fact (including, without\nlimitation, statements that use words such as \"anticipate,\" \"believe,\"\n\"contemplate,\" \"could,\" \"estimate,\" \"expect,\" \"intend,\" \"seek,\" \"may,\"\n\"might,\" \"plan,\" \"potential,\" \"predict,\" \"project,\" \"target,\" \"model,\"\n\"objective,\" \"aim,\" \"upcoming,\" \"should,\" \"will,\" \"would,\" or the negative of\nthese words or other similar expressions) should be considered forward-looking\nstatements. There are a number of important factors that could cause our\nactual results to differ materially from those indicated by the\nforward-looking statements, such as (i) the risk that we may not be able to\nsecure sufficient future funding when needed and as required to advance and\nsupport our existing and planned development programs and operations, (ii) the\nrisk that observations in preclinical studies and early or preliminary\nobservations in clinical studies do not ensure that later observations,\nstudies and development will be consistent or successful, (iii) the risk that\nour research and the research of our collaborators may not be successful, (iv)\nthe risk that our Open-Medicine AI commercialization efforts may not generate\nthe anticipated revenue or achieve the expected market adoption, (v) the risk\nthat no drug product based on our proprietary AI platforms has received FDA\nmarketing approval or otherwise been incorporated into a commercial product,\n(vi) the risk that ongoing partnership and collaborations discussions may not\nresult in definitive agreements on acceptable terms or at all, (vii) market\nand other conditions, and (viii) technical, scientific, regulatory, financial,\ncompetitive, and operational risks and those other factors set forth in the\nRisk Factors sections in our Annual Report on Form 10-K for the year ended\nDecember 31, 2025, filed with the Securities and Exchange Commission on March\n30, 2026.\n\nYou may access our Annual Report on Form 10-K for the year ended December 31,\n2025 under the investor SEC filings tab of our website at\nwww.lanternpharma.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.lanternpharma.com&esheet=54618155&newsitemid=20261008156050&lan=en-US&anchor=www.lanternpharma.com&index=5&md5=3adbbe76685c15c0bdd313fd600e1e9c)\nor on the SEC's website at www.sec.gov\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.sec.gov&esheet=54618155&newsitemid=20261008156050&lan=en-US&anchor=www.sec.gov&index=6&md5=21f96740bc6c4011b71b8467bf1bd4d2)\n. Given these risks and uncertainties, we can give no assurances that our\nforward-looking statements will prove to be accurate, or that any other\nresults or events projected or contemplated by our forward-looking statements\nwill in fact occur, and we caution investors not to place undue reliance on\nthese statements. All forward-looking statements in this press release\nrepresent our judgment as of the date hereof, and, except as otherwise\nrequired by law, we disclaim any obligation to update any forward-looking\nstatements to conform the statement to actual results or changes in our\nexpectations.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261008156050/en/\n(https://www.businesswire.com/news/home/20261008156050/en/)\n\nInvestor Contact\nInvestor Relations\nir@lanternpharma.com (mailto:ir@lanternpharma.com) \n+1-972-277-1136\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw59vX58a-20261008","title":"Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 15th, 2026","author":"Business Wire","ticker":"LTRN","created":"2026-10-08T12:00:01.527Z","tickers":["LTRN"],"exchange":"NASDAQ","article_body":"Lantern Pharma to Present at the ThinkEquity Conference in NYC on October\n15th, 2026\n\nLantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”)\ncompany developing targeted and transformative cancer therapies using its\nproprietary RADR(®) AI and machine learning (“ML”) platform with multiple\nclinical stage drug programs, today announced that Lantern management will be\npresenting at the ThinkEquity Conference on Thursday, October 15, 2026, at\n3:30 p.m. ET at the Mandarin Oriental in New York, NY.\n\n * Webcast Link: \nhttps://event.summitcast.com/view/GXv6JAoMEphytK6ggozCk7/VS4pGMrvkgq2xwHrNQevWX\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fevent.summitcast.com%2Fview%2FGXv6JAoMEphytK6ggozCk7%2FVS4pGMrvkgq2xwHrNQevWX&esheet=54618155&newsitemid=20261008156050&lan=en-US&anchor=https%3A%2F%2Fevent.summitcast.com%2Fview%2FGXv6JAoMEphytK6ggozCk7%2FVS4pGMrvkgq2xwHrNQevWX&index=1&md5=2e0fec7a96fb37b1002bd390822a267d)\n * Conference Registration Link: \nhttps://www.meetmax.com/sched/event_138793/conference_register.html\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.meetmax.com%2Fsched%2Fevent_138793%2Fconference_register.html&esheet=54618155&newsitemid=20261008156050&lan=en-US&anchor=https%3A%2F%2Fwww.meetmax.com%2Fsched%2Fevent_138793%2Fconference_register.html&index=2&md5=7e27767e4ff2a66e32b0c0c28fc19ad7)\nLantern Pharma management will be available for one-on-one meetings held\nthroughout the conference.\n\nAbout Lantern Pharma\n\nLantern Pharma Inc. (NASDAQ: LTRN) is a clinical-stage, AI-driven precision\noncology company developing targeted therapies for high-need cancer\nindications. The Company’s proprietary RADR® AI platform integrates\nmulti-omic biomarker data with clinical outcomes to identify patient subgroups\nmost likely to respond to specific therapies, enabling more efficient clinical\ndevelopment and biomarker-driven trial design. Lantern’s pipeline includes\nLP-300 (HARMONIC™ trial in never-smoker NSCLC), LP-184, and LP-284, with\nadditional preclinical programs identified through RADR®.\n\nFor more information, visit:\n\n * Website: \nwww.lanternpharma.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.lanternpharma.com&esheet=54618155&newsitemid=20261008156050&lan=en-US&anchor=www.lanternpharma.com&index=3&md5=8562d72ec455aa97ec03e0da5129bddc)\n * LinkedIn: \nhttps://www.linkedin.com/company/lanternpharma/\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Flanternpharma%2F&esheet=54618155&newsitemid=20261008156050&lan=en-US&anchor=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Flanternpharma%2F&index=4&md5=0d917bbd2e28f0fe0bf464b8381d22fd)\n * X: @lanternpharma\nForward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nSection 27A of the Securities Act of 1933, as amended, and Section 21E of the\nSecurities Exchange Act of 1934, as amended. These forward-looking statements\ninclude, among other things, statements relating to: future events or our\nfuture financial performance; the potential advantages of our RADR(®) and\nOpen-Medicine AI platforms in identifying drug candidates, accelerating drug\ndevelopment, and generating revenue through software licensing and\nsubscription models; our strategic plans to advance the development of our\ndrug candidates; the planned commercialization of our AI platforms, including\nOpen-Medicine AI; estimates regarding the development timing for our drug\ncandidates and AI platforms; our research and development efforts of our\ninternal drug discovery programs and the utilization of our AI platforms to\nstreamline the drug development process; estimates regarding patient\npopulations, potential markets and potential market sizes; and our plans to\ndiscover and develop drug candidates and to maximize their commercial\npotential by advancing such drug candidates ourselves or in collaboration with\nothers.\n\nAny statements that are not statements of historical fact (including, without\nlimitation, statements that use words such as \"anticipate,\" \"believe,\"\n\"contemplate,\" \"could,\" \"estimate,\" \"expect,\" \"intend,\" \"seek,\" \"may,\"\n\"might,\" \"plan,\" \"potential,\" \"predict,\" \"project,\" \"target,\" \"model,\"\n\"objective,\" \"aim,\" \"upcoming,\" \"should,\" \"will,\" \"would,\" or the negative of\nthese words or other similar expressions) should be considered forward-looking\nstatements. There are a number of important factors that could cause our\nactual results to differ materially from those indicated by the\nforward-looking statements, such as (i) the risk that we may not be able to\nsecure sufficient future funding when needed and as required to advance and\nsupport our existing and planned development programs and operations, (ii) the\nrisk that observations in preclinical studies and early or preliminary\nobservations in clinical studies do not ensure that later observations,\nstudies and development will be consistent or successful, (iii) the risk that\nour research and the research of our collaborators may not be successful, (iv)\nthe risk that our Open-Medicine AI commercialization efforts may not generate\nthe anticipated revenue or achieve the expected market adoption, (v) the risk\nthat no drug product based on our proprietary AI platforms has received FDA\nmarketing approval or otherwise been incorporated into a commercial product,\n(vi) the risk that ongoing partnership and collaborations discussions may not\nresult in definitive agreements on acceptable terms or at all, (vii) market\nand other conditions, and (viii) technical, scientific, regulatory, financial,\ncompetitive, and operational risks and those other factors set forth in the\nRisk Factors sections in our Annual Report on Form 10-K for the year ended\nDecember 31, 2025, filed with the Securities and Exchange Commission on March\n30, 2026.\n\nYou may access our Annual Report on Form 10-K for the year ended December 31,\n2025 under the investor SEC filings tab of our website at\nwww.lanternpharma.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.lanternpharma.com&esheet=54618155&newsitemid=20261008156050&lan=en-US&anchor=www.lanternpharma.com&index=5&md5=3adbbe76685c15c0bdd313fd600e1e9c)\nor on the SEC's website at www.sec.gov\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.sec.gov&esheet=54618155&newsitemid=20261008156050&lan=en-US&anchor=www.sec.gov&index=6&md5=21f96740bc6c4011b71b8467bf1bd4d2)\n. Given these risks and uncertainties, we can give no assurances that our\nforward-looking statements will prove to be accurate, or that any other\nresults or events projected or contemplated by our forward-looking statements\nwill in fact occur, and we caution investors not to place undue reliance on\nthese statements. All forward-looking statements in this press release\nrepresent our judgment as of the date hereof, and, except as otherwise\nrequired by law, we disclaim any obligation to update any forward-looking\nstatements to conform the statement to actual results or changes in our\nexpectations.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261008156050/en/\n(https://www.businesswire.com/news/home/20261008156050/en/)\n\nInvestor Contact\nInvestor Relations\nir@lanternpharma.com (mailto:ir@lanternpharma.com) \n+1-972-277-1136\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-10-08T12:00:01.666861098Z","server_sent_at_ms":1791460801666},"received_at":"2026-10-08T12:00:01.717Z","source_url":"https://www.businesswire.com/news/home/20261008156050/en/"},"analysis":{"id":"152630","press_release_id":"164199","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Lantern Pharma management will present at the ThinkEquity Conference on October 15, 2026, at 3:30 p.m. ET at the Mandarin Oriental in New York.\n\nManagement will also be available for one-on-one meetings throughout the conference, with a webcast available to investors.\n\nThe notice is routine IR scheduling; no new clinical, financial, or strategic information was disclosed.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine conference appearance -- monitor the October 15 presentation for pipeline updates."},"keyFigures":{},"namedEntities":{"people":[],"products":["RADR","LP-300","HARMONIC","LP-184","LP-284"],"companies":[{"name":"Lantern Pharma Inc.","ticker":"LTRN","relationship":"filer"},{"name":"ThinkEquity","relationship":"conference host"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Boilerplate investor-conference presentation notice with no new results, financials, or strategic announcements."},"tickerRelevance":{"others":[],"primary":"LTRN"},"globalImportance":5,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"conference-presentation-notice","issuerAuthored":true}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Lantern Pharma management will present at the ThinkEquity Conference on October 15, 2026, at 3:30 p.m. ET at the Mandarin Oriental in New York.\n\nManagement will also be available for one-on-one meetings throughout the conference, with a webcast available to investors.\n\nThe notice is routine IR scheduling; no new clinical, financial, or strategic information was disclosed.","key_figures":{},"named_entities":{"people":[],"products":["RADR","LP-300","HARMONIC","LP-184","LP-284"],"companies":[{"name":"Lantern Pharma Inc.","ticker":"LTRN","relationship":"filer"},{"name":"ThinkEquity","relationship":"conference host"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-08T12:00:24.685Z","global_importance":5,"audience_relevance":10,"importance_components":{"tickerTier":"micro-cap","eventGravity":"conference-presentation-notice","issuerAuthored":true}},"durationMs":5201,"modelName":"glm-5.3-flashx"}}